Stock Price Forecast

July 1, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sierra Oncology Inc chart...

About the Company

Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.

CEO

Stephen Dilly

Exchange

NASDAQ

Website

www.sierraoncology.com

$0M

Total Revenue

69

Employees

$1B

Market Capitalization

-8.13

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SRRA News

Sierra Oncology (NASDAQ: SRRA)

3y ago, source: The Motley Fool

Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to ...

GSK to buy Sierra Oncology amid pressure to boost drug pipeline

7d ago, source: FXEmpire.com

Britain's GlaxoSmithKline has agreed to buy California-based biopharmaceutical company Sierra Oncology in a deal valued at $1.9 billion, the companies said on Wednesday. By Natalie Grover and ...

CGEM Cullinan Therapeutics, Inc.

23h ago, source: Seeking Alpha

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619 ...

ELEV Elevation Oncology, Inc.

2d ago, source: Seeking Alpha

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.

Patrick J Heron's Net Worth

19d ago, source: Benzinga.com

Who is Patrick J Heron? Patrick J Heron has an estimated net worth of $804 Million. This is based on reported shares across multiple companies, which include Vaxcyte, Inc., Trubion Pharmaceuticals ...

Patrick G Enright's Net Worth

7d ago, source: Benzinga.com

Who is Patrick G Enright? Patrick G Enright has an estimated net worth of $1.94 Billion. This is based on reported shares across multiple companies, which include VALENTIS INC, Inozyme Pharma, Inc ...

Pyxis Oncology, Inc. (PYXS)

3d ago, source: Yahoo Finance

Sullivan, M.D BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to ...

Ikena Oncology Inc IKNA

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

CG Oncology, Inc.

2mon ago, source: CNN

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer.

Elevation Oncology, Inc.

11mon ago, source: CNN

Elevation Oncology, Inc. is a precision oncology company, which engages in the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations.

Pyxis Oncology, Inc. (PYXS)

26d ago, source: Yahoo Finance

Sullivan, M.D BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...